EUVIMED · CrossrefZeitschrift
Clinical & Translational Immunology
ISSN 2050-0068 · Wiley
Neueste Artikel
Randomised controlled phase I trial of a SARS ‐ CoV ‐2 monoclonal antibody
Staphylococcus aureus ‐derived xanthine exacerbates allergic rhinitis‐induced olfactory dysfunction through promoting Th17 cell differentiation and IL ‐ 17A production
M11 ‐ CAR T cells inhibit murine cytomegalovirus in vitro upon recognition of virion‐ and cell‐associated glycoprotein B
A novel surface plasmon resonance approach to assess anti‐dsDNA antibody kinetics and disease severity in systemic lupus erythematosus
Organ‐on‐chip for advancing CAR therapy
Leveraging radiotherapy to improve immunotherapy outcomes: rationale, progress and research priorities
Engineered iPSC ‐derived natural killer cells: recent innovations in translational innate anti‐cancer immunotherapy
T‐cell subsets in Pneumocystis pneumonia
Whole blood transcriptomics reveals granulocyte colony‐stimulating factor as a mediator of cardiopulmonary bypass‐induced systemic inflammatory response syndrome
Fighting flu: novel CD8 + T‐cell targets are required for future influenza vaccines
CD39 expression defines exhausted CD4 + T cells associated with poor survival and immune evasion in human gastric cancer
Chitinase 3‐like 1 expression associated with lymphatic metastasis and prognosis in urothelial carcinoma of the bladder
Optimisation of a primary human CAR‐NK cell manufacturing pipeline
Effects of extremely preterm birth on cytokine and chemokine responses induced by T‐cell activation during infancy
Advances in bacteria‐based drug delivery systems for anti‐tumor therapy
Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma
Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survival
Lymphocyte activation gene 3 served as a potential prognostic and immunological biomarker across various cancer types: a clinical and pan‐cancer analysis
Cerebrospinal fluid YKL‐40 level evolution is associated with autoimmune encephalitis remission
Epstein–Barr virus and multiple sclerosis: moving from questions of association to questions of mechanism
The interaction between Epstein–Barr virus and multiple sclerosis genetic risk loci: insights into disease pathogenesis and therapeutic opportunities
A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases
A case of T‐cell‐Epstein–Barr virus‐haemophagocytic lymphohistiocytosis and sustained remission following ruxolitinib therapy
Assessment of antibodies in the upper and lower human respiratory tract at steady state and after respiratory viral infection
Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma
Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?
Inflammatory cytokines as mediators of retinal endothelial barrier dysfunction in non‐infectious uveitis
Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate
SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models
TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression
EUVIMED